NEW YORK, July 23, 2012 (GLOBE NEWSWIRE) -- Intellect Neurosciences, Inc. (OTCPK:ILNS) announces Dr. Daniel G. Chain, Chairman and CEO, will present at the IBC Antibody Drug Conjugates, Bispecifics & Empowered Antibodies Summit on August 6, 2012 at the Westin San Francisco.
Dr. Chain's presentation, which begins at 11:15 am (PT), focuses on the company's CONJUMAB-A platform technology, including its lead compound, N01-OX2, an antibody drug conjugate being developed for age-related macular degeneration (AMD).
"Intellect Neurosciences is capitalizing on the pathological mechanisms found in Alzheimer's disease that underlie retinal degeneration, particularly AMD. AMD is the leading cause of blindness in people over age 55," said Dr. Chain. "Until now, antibody drug conjugates have been dominated by oncology applications, delivering toxic payloads to selectively kill cancer cells. Our CONJUMAB-A platform turns the approach on its head, instead rescuing cells from the damage caused by amyloidogenic proteins and delivering on-site neuroprotection."
N01-OX2 is a humanized monoclonal antibody against beta amyloid (Aβ) conjugated to melatonin with the aim of preventing the accumulation of toxic Aβ in the retina and delivering on-site neuroprotection to reduce geographical atrophy and neovascularization.
About Intellect Neurosciences
Intellect Neurosciences, Inc., develops innovative approaches aimed at arresting or preventing Alzheimer's disease and other neurodegenerative diseases, with a specific focus on proteinopathies. Intellect's pipeline includes therapeutic vaccines, antibodies and neuroprotective antibody drug conjugates.
The company recently licensed OX1, a small molecule multimodal antioxidant, to ViroPharma, Inc. for Friedreich's Ataxia and other neurodegenerative diseases. For more information, please visit www.intellectns.com.
Safe Harbor Statement Regarding Forward-Looking Statements:
The statements in this release and oral statements made by representatives of Intellect Neurosciences relating to matters that are not historical facts (including, without limitation, those regarding future performance or financial results, the timing or potential outcomes of research collaborations or clinical trials, any market that might develop for any of Intellect's product candidates and the sufficiency of Intellect's cash and other capital resources) are forward-‐looking statements that involve risks and uncertainties, including, but not limited to, the likelihood that actual performance or results could materially differ, that future research will prove successful, the likelihood that any product in the research pipeline will receive regulatory approval in the United States or abroad, or Intellect's ability to fund such efforts with or without partners. Intellect undertakes no obligation to update any of these statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as to the date hereof. Accordingly, any forward-looking statements should be read in conjunction with the additional risks and uncertainties detailed in Intellect's filings with the Securities and Exchange Commission, including those factors discussed under the caption "Risk Factors" in Intellect's Annual Report on Form 10-K (file no. 333-128226), filed on October 13, 2011, and in our Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2012, filed on May 14, 2012.